RNXT
What one share of Renovorx holds
Surgical and Medical Instruments and Apparatus
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (“FDA”)-cleared local drug-delivery device, targeting high unmet medical needs.
Renovorx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.31 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.21 |
| Book value | $0.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.72 | — | −$1.59 | — | −$6.56 |
| 2021 | — | −$1.21 | — | −$1.13 | — | $1.72 |
| 2022 | — | −$1.09 | — | −$0.97 | — | $0.68 |
| 2023 | — | −$0.99 | — | −$1.00 | — | $0.28 |
| 2024 | $0.00 | −$0.40 | $0.00 | −$0.41 | — | $0.19 |
| 2025 | $0.03 | −$0.32 | $0.00 | −$0.31 | — | $0.15 |